Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for PROCEPT BioRobotics's Price-to-Tangible-Book or its related term are showing as below:
MEX:PRCT'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.44 Med: 7.53 Max: 17.39
Current: 3.44
During the past 7 years, PROCEPT BioRobotics's highest Price to Tangible Book Ratio was 17.39. The lowest was 3.44. And the median was 7.53.
MEX:PRCT's Price-to-Tangible-Book is ranked worse than 57.47% of 703
companies
in the Medical Devices & Instruments industry
Industry Median: 2.7
vs MEX:PRCT: 3.44
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
PROCEPT BioRobotics Price-to-Tangible-Book Related Terms
PROCEPT BioRobotics Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for PROCEPT BioRobotics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:PRCT vs BVS, IRMD, LMRI: Price-to-Tangible-Book Comparison
For the Medical Devices subindustry, PROCEPT BioRobotics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
PROCEPT BioRobotics (MEX:PRCT) has a Price-to-Tangible-Book of 3.21 as of Sep. 21, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on PROCEPT BioRobotics and its competitors. According to the industry distribution chart, PROCEPT BioRobotics ranks #404 out of 703 companies in the Medical Devices & Instruments industry, placing it in the top 57.5%.
Is PROCEPT BioRobotics' Price-to-Tangible-Book too high?
PROCEPT BioRobotics' current Price-to-Tangible-Book is 3.21. The Medical Devices & Instruments industry median Price-to-Tangible-Book is 2.70. PROCEPT BioRobotics' value of 3.21 is 18.9% above this industry median. Based on the distribution chart, PROCEPT BioRobotics ranks #404 out of 703 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Price-to-Tangible-Book compare to BVS and IRMD?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #404 out of 703 companies for Price-to-Tangible-Book. This places PROCEPT BioRobotics in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.70. PROCEPT BioRobotics' value of 3.21 is 18.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Devices & Instruments company?
The median Price-to-Tangible-Book among Medical Devices & Instruments companies is 2.70, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROCEPT BioRobotics's current Price-to-Tangible-Book of 3.21 is 18.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on PROCEPT BioRobotics and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Tangible-Book is 2.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current Price-to-Tangible-Book is 3.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
PROCEPT BioRobotics (MEX:PRCT) has a current Price-to-Tangible-Book of 3.21. The stock's GF Value™ is MXN1,504.59, compared to a current price of MXN332.83 — trading 77.9% below its estimated fair value. The current Price-to-Tangible-Book is 3.21 and 18.9% above the Medical Devices & Instruments industry median of 2.70. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For PROCEPT BioRobotics (MEX:PRCT), the current Price-to-Tangible-Book is 3.21 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (MEX:PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of MXN332.83 is trading 77.9% below its estimated GF Value™ of MXN1,504.59.
Key valuation signals for MEX:PRCT:
Price-to-Tangible-Book: 3.21
GF Value™: MXN1,504.59 vs. price of MXN332.83 (77.9% below fair value)
Industry Position: 18.9% above the Medical Devices & Instruments median (#404 of 703)
No single metric tells the full story. See the MEX:PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score
Get the complete analysis for MEX:PRCT
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PRCT has been successfully added to your 
